- Home
- RDZN vs CRBP Comparison
RDZN vs CRBP Comparison
Compare RDZN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDZN | CRBP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | 308 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 184.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RDZN | CRBP |
|---|---|---|
| Price | $1.71 | $7.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 618.3K | ★ 666.2K |
| Earning Date | 02-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $0.81 | $6.73 |
| 52 Week High | $2.56 | $20.56 |
Technical Indicators
Market Signals| Indicator | RDZN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 38.45 |
| Support Level | $1.60 | N/A |
| Resistance Level | $1.99 | $8.87 |
| Average True Range (ATR) | 0.14 | 0.87 |
| MACD | -0.03 | -0.25 |
| Stochastic Oscillator | 8.82 | 9.03 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.